Bio Long Term Debt Total vs Total Stockholder Equity Analysis
TECH Stock | USD 75.38 0.51 0.68% |
Bio Techne financial indicator trend analysis is way more than just evaluating Bio Techne Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bio Techne Corp is a good investment. Please check the relationship between Bio Techne Long Term Debt Total and its Total Stockholder Equity accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Long Term Debt Total vs Total Stockholder Equity
Long Term Debt Total vs Total Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bio Techne Corp Long Term Debt Total account and Total Stockholder Equity. At this time, the significance of the direction appears to have strong relationship.
The correlation between Bio Techne's Long Term Debt Total and Total Stockholder Equity is 0.68. Overlapping area represents the amount of variation of Long Term Debt Total that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of Bio Techne Corp, assuming nothing else is changed. The correlation between historical values of Bio Techne's Long Term Debt Total and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt Total of Bio Techne Corp are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Long Term Debt Total i.e., Bio Techne's Long Term Debt Total and Total Stockholder Equity go up and down completely randomly.
Correlation Coefficient | 0.68 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Long Term Debt Total
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most indicators from Bio Techne's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bio Techne Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. The Bio Techne's current Selling General Administrative is estimated to increase to about 416.7 M. The Bio Techne's current Tax Provision is estimated to increase to about 24.5 M
2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 1.1B | 1.1B | 1.2B | 1.2B | Depreciation And Amortization | 101.1M | 107.2M | 111.7M | 117.3M |
Bio Techne fundamental ratios Correlations
Click cells to compare fundamentals
Bio Techne Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bio Techne fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 2.0B | 2.3B | 2.3B | 2.6B | 2.7B | 2.8B | |
Short Long Term Debt Total | 433.5M | 420.6M | 326.0M | 455.0M | 419.5M | 440.5M | |
Other Current Liab | 8.3M | 62.9M | 69.2M | 45.3M | 63.9M | 67.1M | |
Total Current Liabilities | 106.7M | 152.3M | 176.0M | 128.5M | 159.4M | 167.3M | |
Total Stockholder Equity | 1.4B | 1.6B | 1.7B | 2.0B | 2.1B | 2.2B | |
Property Plant And Equipment Net | 248.3M | 281.7M | 288.8M | 324.5M | 342.4M | 359.6M | |
Net Debt | 286.9M | 221.5M | 153.4M | 274.4M | 267.7M | 281.1M | |
Retained Earnings | 1.1B | 1.1B | 1.1B | 1.3B | 1.3B | 1.4B | |
Cash | 146.6M | 199.1M | 172.6M | 180.6M | 151.8M | 89.5M | |
Non Current Assets Total | 1.5B | 1.8B | 1.7B | 2.0B | 2.1B | 2.2B | |
Non Currrent Assets Other | 13.5M | 11.6M | (88.2M) | 285.3M | 12.1M | 16.3M | |
Cash And Short Term Investments | 270.9M | 231.6M | 247.0M | 204.3M | 152.9M | 137.1M | |
Net Receivables | 122.5M | 145.4M | 194.5M | 218.5M | 241.4M | 253.5M | |
Common Stock Shares Outstanding | 157.6M | 161.9M | 164.1M | 161.9M | 160.8M | 169.2M | |
Liabilities And Stockholders Equity | 2.0B | 2.3B | 2.3B | 2.6B | 2.7B | 2.8B | |
Non Current Liabilities Total | 539.7M | 539.4M | 417.8M | 543.7M | 475.6M | 499.4M | |
Inventory | 103.2M | 116.7M | 141.1M | 171.6M | 179.7M | 188.7M | |
Other Current Assets | 24.3M | 16.9M | 22.9M | 27.1M | 43.4M | 45.6M | |
Other Stockholder Equity | 420.5M | 534.4M | 653.7M | 721.5M | 820.3M | 861.4M | |
Total Liab | 646.4M | 691.7M | 593.8M | 672.2M | 635.0M | 666.8M | |
Total Current Assets | 520.9M | 510.6M | 605.6M | 621.5M | 617.4M | 648.3M | |
Short Term Debt | 22.0M | 35.7M | 36.4M | 22.4M | 25.8M | 27.1M | |
Accounts Payable | 63.3M | 29.4M | 33.9M | 25.7M | 38.0M | 39.9M | |
Intangible Assets | 516.5M | 616.0M | 531.5M | 534.6M | 507.1M | 532.4M | |
Property Plant And Equipment Gross | 248.3M | 281.7M | 288.8M | 324.5M | 599.0M | 628.9M | |
Accumulated Other Comprehensive Income | (97.2M) | (57.3M) | (75.2M) | (66.1M) | (78.3M) | (74.4M) | |
Common Stock Total Equity | 385K | 390K | 392K | 1.6M | 1.8M | 1.9M | |
Short Term Investments | 124.3M | 32.5M | 74.5M | 23.7M | 1.1M | 1.0M | |
Common Stock | 385K | 390K | 392K | 1.6M | 1.6M | 1.7M | |
Other Liab | 110.9M | 143.0M | 116.2M | 99.9M | 114.9M | 97.2M | |
Other Assets | 13.5M | 11.6M | 46.8M | 12.6M | 14.5M | 8.8M | |
Long Term Debt | 344.2M | 328.8M | 243.4M | 350M | 319M | 335.0M | |
Property Plant Equipment | 248.3M | 281.7M | 288.8M | 226.2M | 260.1M | 139.9M | |
Good Will | 728.3M | 843.1M | 822.1M | 872.7M | 972.7M | 1.0B | |
Current Deferred Revenue | 13.0M | 19.0M | 23.4M | 23.1M | 27.9M | 29.3M | |
Net Tangible Assets | 136.3M | 112.2M | 347.4M | 652.9M | 587.6M | 617.0M | |
Retained Earnings Total Equity | 1.1B | 1.1B | 1.1B | 1.3B | 1.5B | 812.3M | |
Capital Surpluse | 420.5M | 534.4M | 653.7M | 721.5M | 829.8M | 871.3M | |
Deferred Long Term Liab | 101.1M | 93.1M | 99.0M | 89.0M | 102.3M | 67.5M |
Currently Active Assets on Macroaxis
When determining whether Bio Techne Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Techne's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Techne Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Techne Corp Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.32) | Dividend Share 0.32 | Earnings Share 0.95 | Revenue Per Share 7.424 | Quarterly Revenue Growth 0.045 |
The market value of Bio Techne Corp is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Techne's value that differs from its market value or its book value, called intrinsic value, which is Bio Techne's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Techne's market value can be influenced by many factors that don't directly affect Bio Techne's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Techne's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.